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A B S T R A C TBackground and Objective: The Treatment Satisfaction with Medi-
cines Questionnaire (SATMED-Q) has shown appropriate psycho-
metric properties exploring patients’ satisfaction with treatment.
Responsiveness (sensitivity to change) and known-group validity,
however, still remained unknown. Thus, the goal of this study was
to explore such psychometric properties for the SATMED-Q. Methods:
We used data from a 6-month prospective study carried out in pain
clinics, which included patients with chronic refractory pain of
neuropathic origin who needed a change in their therapies. Sensitiv-
ity to change was assessed by comparing changes in the total and
domain scores between baseline and end-of-trial visits according to
patients’ response criterion: pain reduction 50% or more (responder).
Also, correlations between changes in pain intensity and satisfaction
scores were computed. Known-groups validity was explored by
comparing the degree of satisfaction between groups of different
levels of pain. Results: The sample was formed with 728 subjects (57.8
years, 61.0% women). After changing their therapy, 47% of the patientssee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.08.2224
as@pfizer.com.
ondence to: Javier Rejas, Health Economics and Ou
sarial de la Moraleja, 28108 Alcobendas, Madrid, Swere considered responders, and pain intensity was reduced by an
average of 42.9%  32.4% (Po 0.001), which was significantly corre-
lated (r ¼ 0.524, Po 0.001) with total treatment satisfaction
improvement. The total score in the SATMED-Q was significantly
higher in responders than in nonresponders: 80.9 (79.6–82.3) versus
66.5 (65.0–98.0) (Po 0.001). Also, the instrument showed different
scores of satisfaction according to different degrees of pain (mild,
moderate, severe), F ¼ 116.8 (Po 0.001) in the total composite score
and domains. Conclusion: The SATMED-Q was sensitive to changes
in patients’ satisfaction with treatment. In addition, patients’different
heath statuses are correlated with different levels of satisfaction with
treatment.
Keywords: known-group validity, neuropathic pain, responsiveness,
satisfaction, SATMED-Q, sensitivity to change..
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In the treatment of chronic illnesses, the traditional measures of
morbidity and mortality, together with other biomedical para-
meters, only partially evaluate the effectiveness of drugs and
other medical interventions that, while prolonging patient life, do
not provide a cure. When the administered treatments do not
affect survival rates, when the differences among them are
not dramatic, and when the treatments and other medical
interventions cause serious side effects for months or even
years, the need arises to evaluate effectiveness in other terms
[1]. Health outcomes research, a relatively recent discipline,
focuses on the measurement of disease and treatment impact
on patient-perceived health, among other things, provides an
answer to these new requirements of modern medicine [2,3].
Patient satisfaction is related to all aspects of health care that are
of relevance to health. The concept includes satisfaction with
both the medical care received and with the specific treatments
prescribed by clinicians [4,5]. Satisfaction with medication and
with medical treatment appears to be related to patientadherence or compliance with treatment and constitutes a
quality indicator that can be used to improve health care and
one that affects patient preferences [4,6–12].
The Treatment Satisfaction with Medicines Questionnaire
(SATMED-Q) is a multidimensional generic questionnaire, brief,
feasible, and easy to self-administer, with good metric properties
of reliability and validity [13]. The questionnaire has been
designed for use in patients with any chronic illness and under-
going any type of prolonged pharmacological treatment. The
questionnaire was developed assuming the classical test theory
framework [14,15], and such properties have been proven in
routine medical practice for chronic health conditions. However,
responsiveness (sensitivity to change) and known-group validity
properties of the instrument were still unknown. Responsiveness
of a scale refers to its ability to detect a change that has actually
occurred, and it is an important feature when assessing treat-
ment effectiveness. Known-group validity refers to the ability of a
tool to differentiate between groups of subjects that are known to
be different in terms of health status [15]. Quantifying changes in
SATMED-Q scores after a medical intervention should improveSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
tcomes Research Department, Pfizer, S.L.U., Avenida de Europa,
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extend our understanding of the meaning and clinical value of
change in scores for this tool. Thus, the goal of this research was
to explore these particular psychometric properties in the
SATMED-Q.Table 1 – Demographic and clinic characteristics of
patients included in the study.
N 728
Age (y) 57.8  13.8
Sex (women) 444 (61.0%)
BMI (kg/m2) 26.7  4.2
DN4 (points) 6.6  1.5
Pain duration (y) 2.6  3.6
Pain intensity (VAS, mm) 74.2  15.1
Mild (o40 mm) 15 (2.1%)
Moderate (40–o70 mm) 232 (31.9%)
Severe (Z70 mm) 480 (66.0%)
Neuropathic pain type
Diabetic or other neuropathy 106 (14.6%)
Neuralgia 175 (24.0%)
Radiculopathy 321 (44.1%)
Plexopathy 47 (6.5%)
Entrapping syndromes 93 (12.8%)
Complex-regional painful syndrome 41 (5.6%)
Phantom limb syndrome 11 (1.5%)
Central neuropathic pain 29 (4.0%)
Neuropathic oncologic pain 23 (3.2%)
Postsurgery and/or trauma 23 (3.2%)
Others 31 (4.3%)
HADS
Anxiety subscale (0–21) 9.6  4.2
Depression subscale (0–21) 10.6  4.6
MOS Sleep Scale
Summary index (0–100) 47.1  19.0
Number of sleep hours per day (0–24) 5.6  1.6
WHODAS II-12 items
Total score (0–100) 44.7  19.7
Level of interference of pain with
patient’s life (1–5)
3.4  1.0
None 19 (2.9%)
Mild 87 (13.0%)
Moderate 259 (38.8%)
Severe 218 (32.7%)
Extreme 84 (12.6%)
Note. Values are mean (SD) or n with % relative to total sample.
Patients may have pain of more than one origin. Some patients did
not complete all questionnaires.
BMI, body mass index; HADS, Hospital Anxiety and Depression
Scale; MOS, Medical Outcomes Study; VAS, visual analogue scale
for pain (0 ¼ no pain, 100 ¼ unbearable pain); WHODAS II, World
Health Organization Disability Assessment Scale II.Methods
Design of the Study
This research was a secondary objective of a prospective study
designed to ascertain the reasons for referral and clinical man-
agement of patients with neuropathic pain refractory to analge-
sic treatment who were referred to pain clinics for pain
management and control [16]. In brief, this multicenter, prospec-
tive, observational study was conducted under usual clinical
practice conditions as regards treating disease and managing
patients according to the practitioner’s judgment. Pain clinics
throughout the country were engaged to participate in this
research, and physicians were instructed to request patient
informed consent prior to participation in the study in all cases.
The protocol was reviewed and approved by the Clinical Research
Ethics Committee of the Hospital General de Valencia, in Valen-
cia, Spain, and it was conducted in accordance with the Declara-
tion of Helsinki. The study, carried out between February 2008
and April 2010, included three visits: baseline, month 3, and
month 6 (end of trial). Pain intensity was evaluated at the three
study visits, along with the other outcomes (see below).
Subjects
For this study, patients were consecutively recruited at the
participating pain clinics. Pain clinics were selected at random
throughout the country on the basis of regional population
density. Characteristics of the enrolled sample are shown in
Table 1. In brief, patients were selected from among those
referred to pain clinics for refractoriness of pain, regardless of
the type of physician referring the patient. This meant that it was
felt that patients needed a change in their therapeutic approach
to reduce the baseline intensity of pain associated with the
neuropathic component of that pain. Patients had to meet the
following study inclusion criteria: outpatients of either sex, older
than 18 years, diagnosed with neuropathic pain by using stan-
dard procedures confirmed by a score greater than four points on
the Spanish version of the Douleur Neuropathique 4 questions
scale [17], which was used to identify patients with neuropathic
pain. Patients must have been treated for more than 6 months
with an analgesic for their painful condition and must have had
the ability to understand and answer the health questionnaires
used in the study (written in Spanish) and, finally, must have
been willing to sign the informed consent form.
No prestudy sample size determination was carried out for the
analysis included here. The sample size determination was calcu-
lated for the main objective of the study, which consisted of
analyzing pain reduction after changing the prior analgesic ther-
apy, and also to describe the type of patients referred to pain
clinics for pain control, including the associated pain diagnosis,
type of physician referring the patient, and so on. A sample of 728
subjects finally enrolled in this trial was considered sufficient to
perform the corresponding analyses to test known-group validity
and ability of the instrument to be responsive (sensitive to change).
Scales
The SATMED-Q is a multidimensional generic questionnaire,
brief (17 Likert-type items), feasible, and easy to self-administer
[13]. It has been designed for use with patients presenting withany chronic illness and taking any type of prolonged pharmaco-
logical treatment. The instrument is composed of six domains
exploring actual satisfaction with drug efficacy, side effects,
convenience of use, medical care, impact on activities of daily
living, and general satisfaction. It also provides a total score for
treatment satisfaction with medicines by adding up all domains.
Totaling the direct scores of the items yields a total composite
score ranging between 0 and 68. The resultant total composite
score can be transformed to a more intuitive and easier to
understand metric with a minimum of 0 and a maximum of
100, using the following expression:
Y0 ¼½ðYobsYminÞ=ðYmaxYminÞ  100
where Ymax is 68 (maximum total score), Ymin is 0 (minimum total
score), Yobs is the total patient score, and Y’ is the transformed
score. A similar expression can be used to change the metric of
each individual domain.
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using a 10-cm visual analogue pain scale drawn on paper with
two anchors: no pain and unbearable pain [18]. Patients were
invited to make a mark on the line at the level of their perceived
pain at the visit to the pain clinic, based on the two aforesaid
anchors. The World Health Organization Disability Assessment
Schedule II (WHODAS II) [19] is a multidimensional instrument
developed for measuring disability, which may be self-
administered or interviewer-administered. The complete version
of the instrument contains 36 items on functioning and disability
with a recall period of 30 days, and comprises six domains:
Understanding and communicating, Getting around, Self-care,
Getting along with others, Life activities (household and school
or work), and Participation in society. Items can be scored on a
five-point scale ranging from 1 (none) to 5 (extreme/cannot do).
For all domains, the WHODAS II provides different profiles and a
single disability summary score, which can be computed by using
the SPSS syntax available through the WHO. Scores may vary from
0 to 100, where higher scores reveal greater disability. A shorter,
12-item version of the instrument was also developed and is
recommendable for epidemiological studies and routine outcome
assessment or when domain-specific information regarding func-
tioning is not required [19]. That version was utilized in this study.
The Hospital Anxiety and Depression Scale (HADS) was
initially developed to detect anxiety and depressive disorders in
a hospital setting [20], although its use has evolved to other
clinical settings. The HADS is a 14-item, self-administered tool
with inquiries about the symptoms of anxiety and depression in
the previous week. Each item is rated on a Likert-type scale with
four categories scored from 0 to 3, which ask for the frequency
and/or intensity of the symptom. The HADS is composed of two
domains or subscales of seven items each, exploring anxiety and
depression, respectively. Total scoring in each domain may range
from 0 to 21 points.
The Medical Outcomes Study Sleep Scale assesses the quality
and quantity of sleep [21]. The questionnaire is self-administered
and consists of 12 items assessing the key constructs of sleep.
Patients are asked to recall sleep-related activities over the past 4
weeks. Instrument scoring results in six subscales or domains:
sleep disturbance (four items), snoring (one item), awaken short
of breath or with headache (one item), quantity of sleep (one
item), optimal sleep (one item), sleep adequacy (two items), and
daytime somnolence (three items). In addition, a summary index
of sleep problems may also be constructed with nine items to
provide a composite score. Quantity of sleep is scored as the
average hours slept per night. The other scales and composite
measurements are scored on a transformed 0 to 100 metric,
where higher scores indicate more of the concept being assessed.
Statistical Analysis
Descriptive statistics were calculated by using measures of
central tendency and dispersion, and the Kolmogorov-Smirnov
test was applied to test for a normal distribution of the sample.
Missing data were imputed by means of a simple last-
observation-carried-forward procedure by using data available
at the 3-month visit. Responsiveness in this study was defined as
the ability of the SATMED-Q to detect clinically relevant changes
over time at the end-of-trial (6-month) visit. This was assessed in
several ways. First, an assessment was made of the correlation
between mean changes in pain score and mean variations in
SATMED-Q scores, as measured by the total composite score and
by the individual domains as well. Correlation analysis was
performed by computing the Pearson product-moment coeffi-
cient. Second, sensitivity to change was also assessed by compar-
ing changes in the total and domain scores between the baseline
and end-of-trial visits among patients classified according to thefollowing response criterion: pain reduction 50% or more (respon-
der). The comparison was also performed by using a second
response criterion of a baseline pain reduction of 30%. These two
criteria were used because an early recommendation of the
IMMPACT consensus review applied to core outcome measures
for chronic pain clinical trials [22]. On a global level, an early
recommendation of the IMMPACT consensus review was that a
50% and 30% change in self-reported pain be used as a general
barometer of positive clinical change. Nevertheless, this was
merely a consensus decision based on a general review of
numerous clinical trials that used different treatment modalities
and statistical methods. Comparisons were carried out by esti-
mating an analysis of covariance model, adjusting for the level of
pain intensity at the baseline visit. The 95% confidence intervals
were also computed for adjusted mean differences and Cohen’s
effect sizes (ESs). The ES was computed according to the method
used by Kazis et al. [23], that is, dividing the difference in the
mean change responses by the baseline SD. The magnitude of all
ESs was interpreted as recommended, considering 0.2 a low ES,
0.5 moderate, and 0.8 high, irrespective of the sign [23]. Third, it
was hypothesized that patient satisfaction with pharmacological
treatment in this sample should also correlate with the so-called
pain triad, which consists of the presence of associated mood
symptoms (depression and anxiety), disability, and sleep pro-
blems. Then, partial correlations (adjusted for pain intensity
change) were calculated between changes in the SATMED-Q
and changes in HADS domain scores, WHODAS II 12-item
summary index, Medical Outcomes Study Sleep Scale summary
index, and the number of hours of sleep per night, respectively.
Known-group validity was assessed through the total score
and domains of the SATMED-Q that explore the differences in the
average satisfaction score when the sample is grouped according
to the level of pain (mild, moderate, or severe) at the end-of trial
visit. The level of pain was stated according to the score on a 10-
cm visual analog pain scale with two anchors: no pain and
unbearable pain. The intensity of pain was grouped into mild
(0–o40 mm), moderate (40–o70 mm), and severe (Z70 mm)
according to Zelman et al. [24]. Known-group validity was also
tested according to the level of interference of pain with daily
activity (none, mild, moderate, severe, or extreme) at the end-of-
trial visit by using the corresponding WHODAS II scale item.
All tests were two-tailed and an error of less than 0.05 was
considered significant. Bonferroni adjustment was used for
multiple comparisons when appropriate. All analyses were per-
formed by using IBM SPSS Statistics software version 19.0.Results
The sample included 755 subjects with refractory pain of neuro-
pathic origin, of whom 728 (96.4%) met the inclusion and
exclusion criteria and were considered evaluable. Sixty-one
percent of the patients (n ¼ 444) were women and the mean
age of patients in the sample was 57.8  13.8 years. In 333 (45.7%)
subjects, refractoriness of pain was caused by the use of analge-
sics at subtherapeutic doses, and in 334 (45.9%) by the use of
analgesics not indicated to treat neuropathic pain. The remaining
causes (n ¼ 61; 8.4%) included poor tolerability, lack of conve-
nience of use, or other reasons. A total of 100 (14.2%) patients
withdrew from the study before its completion, because of loss
to –follow-up (n ¼ 50; 6.9%), side effects (n ¼ 12; 1.6%), lack of
effectiveness (n ¼ 16; 2.2%), or other reasons (22; 3.0%), including
patient’s decision, protocol violation, or unknown. Baseline total
SATMED-Q score and domains were not statistically different
between study completers and subjects lost to follow-up: total
SATMED-Q score 51.2 (17.4) versus 50.9 (19.7) (P ¼ 0.843). Table 1
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subjects in this study, including the mean baseline values on
scales measuring pain intensity and associated mood distur-
bances (symptoms of anxiety and depression), disability, and
sleep problems.
Sensitivity to Change
After referral to pain clinics and changing their therapy, 47% (n ¼
342) of the subjects were considered responders (pain intensity
50% of the baseline value or lower) at the end-of-trial visit. Pain
intensity was reduced by an average of 42.9%  32.4% (ES ¼ 2.48,
Po 0.001) (Table 2), which was significant and negatively corre-
lated (r ¼ 0.524, P o 0.001) with treatment satisfaction improve-
ment on the SATMED-Q, whose total score varied from
50.3  17.3 to 74.2  14.4 points (ES ¼ 1.38, Po 0.001) (Table 2).
Pearson’s r coefficients between pain intensity reduction and
SATMED-Q domain changes were negative and significant, ran-
ging between 0.189 (undesirable side effects) and 0.465 (treat-
ment effectiveness, Po 0.01 in all cases). Changes in SATMED-Q
Treatment side effects, Medical care, and Convenience of use
domains were small to moderate in magnitude, and correlations
with pain change were also moderate, although significant. ESs
and correlations were substantial in the other SATMED-Q
domains due to the observed improvement in pain intensity
change (Table 2).
The mean total SATMED-Q score was significantly higher in
responders than in nonresponders (50% pain reduction criterion);
80.9 (79.6–82.3) versus 66.5 (65.0–68.0), respectively (ES ¼ 0.83,
Po 0.001) (Fig. 1, graph A). A similar finding was also observed
for the 30% pain reduction criterion, showing a larger ES (0.93)
in mean total score difference between responders and non-
responders (Fig. 1, graph B). Large ESs were observed in the
questionnaire domains exploring the effectiveness of the new
therapy (satisfaction with treatment effectiveness and impact on
activities of daily living), while ESs were moderate or small in the
other domains, for both the 50% and 30% pain responder criteriaTable 2 – Changes in the SATMED-Q total score and by domain
Pearson’s coefficients of correlation between changes.
Domain Baseline
score
EOT visit
score
Change at
(95%
Pain intensity
(VAS, mm)
74.2  15.1 36.8  21.2 37.4 (35.7
SATMED-Q
Treatment effectiveness
(0–100)
32.4  25.4 69.9  22.5 37.5 (35.2–39
Convenience of use
(0–100)
58.4  24.4 72.7  19.7 14.3 (12.5–16
Impact on activities of
daily living (0–100)
31.2  26.6 65.8  23.6 34.6 (32.2–37
Medical care (0–100) 64.7  27.2 82.6  15.7 17.9 (15.9–19
Undesirable side effects
(0–100)
74.7  26.6 79.8  20.3 5.1 (3.2–7.1)
Global satisfaction
(0–100)
45.0  29.9 77.1  19.5 32.0 (29.6–34
Total composite score
(0-100)
50.3  17.3 74.2  14.4 23.9 (22.4–25
Notes. Data are mean  SD or mean difference with 95% CI.
CI, confidence interval; EOT, end of trial; SATMED-Q, Treatment Satisfacti
(0 ¼ no pain, 100 ¼ unbearable pain).
* P o 0.001 versus baseline.
† Po 0.001.(Fig. 1). However, the change in treatment satisfaction was
significantly higher in responders than in nonresponders, irre-
spective of the responder criterion used, for both total score and
all domains assessed (Table 3). The magnitude of differences
between groups of responders and nonresponders was of mod-
erate to large ES for total score and the majority of instrument
domains, meaning that the SATMED-Q was able to detect differ-
ent effects of pain reduction on patient satisfaction.
The third step undertaken to test sensitivity to change of the
SATMED-Q was to explore the correlation between changes in
patient-reported outcomes related to pain intensity (sleep dis-
turbances and hours of sleep, anxiety and depressive symptoms,
and disability) and treatment satisfaction variations in total and
domain scores (Table 4). After controlling for the effect of change
in pain, mood, sleep, and disability, patient-reported outcomes
still significantly correlated with changes in SATMED-Q total and
domain scores, although most of these correlations were small to
moderate. For example, a change in SATMED-Q total score
moderately and significantly (Po 0.01) correlated with end-of-
trial changes in score for mood symptoms, disability, and sleep
disturbances (Table 4).
Known-Group Validity
The instrument attained different mean satisfaction scores
according to different degrees of pain (mild, moderate, severe)
as classified by using the visual analogue scale of pain: F ¼ 116.8
(P o 0.001) in the total composite score. F values were also
significant in all questionnaire domains (P o 0.001 in all cases),
with values ranging from 13.6 to 92.9 (Table 5). Similarly, total
composite scores and all domain scores of the SATMED-Q were
significantly different when subjects were classified according to
the level of disability measured by the WHODAS II scale, with F
values of 44.2 in the total score and between 11.0 and 49.7 in the
domains of the instrument (Table 6). A consistent linear relation-
ship between the degree of pain or disability and patient satisfac-
tion could be always observed in the total composite score and ins, and variation of pain intensity at the EOT visit, and
EOT visit
CI)
Cohen’s
effect size
Pearson’s r correlation with
change in pain intensity
to 39.1) 2.48 –
.7) 1.48 0.465†
.1) 0.59 0.247†
.0) 1.30 0.471†
.9) 0.66 0.275†
0.19 0.189†
.5) 1.07 0.420†
.4) 1.38 0.524†
on with Medicines Questionnaire; VAS, visual analogue scale for pain
Fig. 1 – SATMED-Q total score and by domains at end-of-trial visit, according to pain responder criterion; reduction of
baseline pain intensity by 50% (graph A) or 30% (graph B). Values are mean with 95% confidence intervals. yPo 0.001
between-response groups; ’ nonresponders, m responders. Cohen’s effect sizes in brackets. SAT-C.U., convenience of use;
SAT-EFFECT., effectiveness; SAT-G.S., global satisfaction; SAT-IMPACT., impact on activities of daily living; SAT-M.C., medical
care; SAT-S.E., side effects.
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pain (or disability), the lower the level of patient satisfaction.Discussion
It is increasingly being recognized that the viewpoint of the
patient should be taken into account when evaluating a medical
treatment. One important aspect of such a patient-oriented
evaluation is patient satisfaction with treatment or treatment
satisfaction. Treatment satisfaction is a relatively recent area of
interest within health outcome research. It appears to beincreasingly used as a patient-reported outcome when testing
new or existing treatments [25]. Patient satisfaction with the
pharmacologic treatment is of growing concern in clinical prac-
tice. On the one hand, this is because satisfaction helps to
evaluate the efficacy and convenience of the medication pro-
vided. On the other hand, this is because treatment satisfaction
is associated with increased patient adherence to therapy and
with greater patient desire to continue using the drug [26,27].
Hence, treatment satisfaction may help predict treatment com-
pliance and improve the effectiveness of the administered
therapy. This results in closer follow-up of those patients
expected to adhere less to treatment. Last, treatment satisfaction
Table 3 – Changes in the SATMED-Q to.tal score and by domains, at end-of-trial visit, according to pain responder criterion.
SATMED-Q domain Reduction of baseline pain
intensity by 50%
Difference; P value Cohen’s effect size
Responder Nonresponder
Treatment effectiveness (0–100) 48.1 (44.8–51.5)† 21.4 (17.8–25.1)† 26.7 (21.8–31.6)o0.001 1.04
Convenience of use (0–100) 19.4 (16.6–22.2)† 6.7 (3.7–9.8)† 12.7 (8.5–16.8) o0.001 0.51
Impact on activities of daily living (0–100) 45.0 (41.7–48.3)† 19.0 (15.4–22.6)† 26.0 (21.1–30.9)o0.001 0.98
Medical care (0–100) 25.7 (22.8–28.6)† 11.6 (8.5–14.8)† 14.0 (9.8–18.3) o0.001 0.51
Undesirable side effects (0–100) 11.0 (7.6–14.5)† 2.0 (–1.7 to 5.7) 9.0 (4.0–14.1) o0.001 0.31
Global satisfaction (0–100) 44.6 (41.2–48.0)† 18.9 (15.3–22.6)† 25.6 (20.6–30.6)o0.001 0.85
Total composite score (0–100) 31.8 (29.6–31.4)† 12.6 (10.2–15.0)† 19.2 (15.9–22.5)o0.001 1.13
SATMED-Q domain Reduction of baseline pain
intensity by 30%
Difference; P value Cohen’s effect sizez
Responder Nonresponder
Treatment effectiveness (0–100) 42.2 (39.4–45.1)† 14.1 (8.8–19.3)† 28.2 (22.2–34.2)o0.001 1.08
Convenience of use (0–100) 15.7 (13.3–18.1)† 6.2 (1.7–10.6)† 9.5 (4.4–14.6) o0.001 0.38
Impact on activities of daily living (0–100) 39.9 (37.1–42.7)† 9.7 (4.5–14.9)† 30.2 (24.3–36.1)o0.001 1.13
Medical care (0–100) 22.4 (19.9–24.8)† 8.5 (4.0–13.1)† 13.8 (8.6–19.0) o0.001 0.51
Undesirable side effects (0–100) 9.5 (6.6–12.4) 2.6 (7.9 to 2.7) 12.1 (6.0–18.1) o0.001 0.42
Global satisfaction (0–100) 39.2 (36.4–42.1)† 10.3 (4.9–15.7)† 28.9 (22.8–35.0)o0.001 1.01
Total composite score (0–100) 27.4 (25.5–29.3)† 7.1 (3.6–10.7)† 20.2 (16.2–24.3)o0.001 1.15
Notes. Values are adjusted (by baseline pain intensity) for mean change at end-of-trial visit with 95% confidence interval; P value corresponds
to adjusted (by baseline pain intensity) least square mean difference between response groups. Bonferroni adjustment was applied for
multiple comparisons. Not significant if not indicated.
SATMED-Q, Treatment Satisfaction with Medicines Questionnaire.
* P o 0.01 versus baseline.
† Po 0.001 versus baseline.
z Effect size calculated, in each domain or total composite score, as change difference between response groups divided by pooled SD at
baseline visit.
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which is critical for achieving therapeutic goals, and thus correct
disease management in real-world practice [28,29].
This study was conducted to explore the ability of the
SATMED-Q to detect changes in patient satisfaction with
medicine-based therapy. Thus, the novelty of the study consistsTable 4 – Pearson’s coefficients of correlation between changes
in patient-reported outcome measurements at end-of-trial visit.
SATMED-Q domain Hospital Anxiety and
Depression Scale
Anxiety
subscale
Depression
subscale
Su
Treatment effectiveness (0–100) 0.227 0.226 
Convenience of use (0–100) 0.136 0.224 
Impact on activities of daily
living (0–100)
0.238 0.277 
Medical care (0–100) 0.173 0.232 
Undesirable side effects (0–100) 0.093† 0.093† 
Global satisfaction (0–100) 0.288 0.306 
Total composite score (0–100) 0.313 0.362 
Note. Data are partial Pearson r coefficients adjusted for change in pain
MOS, Medical Outcomes Study; SATMED-Q, Treatment Satisfaction with
Disability Assessment Schedule II.
* P o 0.01.
† Po 0.05.of testing the responsiveness and known-group validity of the
SATMED-Q. These properties had not yet been explored. Overall,
the total SATMED-Q score was highly responsive after changing
pain therapy, which showed an important improvement over
baseline pain intensity. As expected, analyses indicated that the
domains most sensitive to change were most related to thein the SATMED-Q total score and by domains, and variations
MOS Sleep Scale WHODAS II
Summary index
mmary
index
Number of hours of
sleep per night
0.183 0.166 0.182
0.162 0.118 0.134
0.208 0.197 0.246
0.241 0.168 0.222
0.154 0.005 0.111
0.319 0.224 0.243
0.336 0.234 0.302
intensity at end-of-trial visit.
Medicines Questionnaire; WHODAS II, World Health Organization
Table 5 – Known-group validity of the SATMED-Q by the level of intensity of pain at EOT visit.
Domain Group by intensity of
pain at EOT visit
Mean 95% CI F (P value)
Treatment effectiveness Mild 77.8 75.7–79.8
Moderate 60.8 58.0–63.7 92.9 (Po 0.001)
Severe 41.9 36.3–47.5
Convenience of use Mild 75.6 73.7–77.5
Moderate 69.3 66.7–71.9 13.6 (Po 0.001)
Severe 63.5 58.3–68.7
Impact on activities of daily living Mild 73.3 71.1–75.4
Moderate 56.5 53.5–59.5 85.1 (Po 0.001)
Severe 37.6 31.7–43.4
Medical care Mild 87.0 85.5–88.5
Moderate 79.3 77.2–81.4 26.4 (Po 0.001)
Severe 74.7 70.6–78.8
Global satisfaction Mild 84.1 82.3– 85.9
Moderate 71.7 69.2–74.2 77.8 (Po 0.001)
Severe 54.2 49.3–59.1
Undesirableside effects Mild 84.2 82.3–86.1
Moderate 78.0 75.4–80.6 24.1 (Po 0.001)
Severe 65.8 60.6–71.0
Total composite score Mild 80.0 78.7–81.3
Moderate 68.6 66.9–70.4 116.8 (Po 0.001)
Severe 55.0 51.6–58.5
Note. Mild (n ¼ 443; 60.9%), moderate (n ¼ 221; 30.3%), and severe (n ¼ 63; 8.7%) pain;o40, Z40–o70, Z70 mm on the visual analogue scale for
pain. Values are adjusted for baseline pain intensity score.
CI, confidence interval; EOT, end of trial; SATMED-Q, Treatment Satisfaction with Medicines Questionnaire.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 8 8 – 9 694evaluation of change in treatment effectiveness. Furthermore,
the intensity of response as measured by the percentage of pain
reduction at the end-of-trial visit was significantly and consis-
tently associated with the level of patient satisfaction with
medicines; the more the pain is reduced, the more the patient
satisfaction with therapy is increased. Furthermore, other pain-
related attributes, such as symptoms of anxiety and depression,
disability, and sleep disturbances, consistently correlated with
changes in patient satisfaction with treatment. Additional evi-
dence supporting the ability of the instrument to detect changes
in satisfaction was that satisfaction domains relative to medical
care and side effects were hardly affected, because such
aspects of medical intervention were not modified or simply
did not occur.
However, the domains of medical care or convenience of use
of treatments prescribed by physicians, which were supposed not
to have changed, actually showed small to moderate ESs of the
magnitude of changes. As mentioned, there were no reasons why
these aspects of therapy would have to change in this sample of
subjects. The main reason for changing the therapy analyzed
here was lack of efficacy or poor response in the management of
pain, regardless of the cause, but hardly any reason related to
side effects, convenience of use, or medical care. The study also
had the chance to show the ability of the instrument to classify
different groups of patients according to the degree of satisfac-
tion with medicine effectiveness. In this sense, for different
levels of actual pain intensity or patient disability related to pain,
the SATMED-Q scored differently, showing a linear relationship:
the higher the pain intensity or disability, the lower the patients’
satisfaction with their drug-based therapy.
Various authors have questioned whether satisfaction with
the medication and with medical treatment influences treatment
adherence [30,31]. This study found significant correlations
between satisfaction and health domains related to pain, such
as disability, symptoms of anxiety and depression, and,
obviously, the main reason for changing the therapy:improvement in pain intensity. As most of the patients com-
pleted the study (492%), it could be reasonable to conclude that
adherence to treatment in this study was good and thus related
to patient satisfaction with treatment. However, compliance was
not assessed in this study, although, again, according to the
efficacy results of changing the therapy, one may hypothesize
that it also should be good. This is important, because it is well
known that the probability of achieving good disease control, at
least in many health conditions, is almost four times higher in
patients with good adherence [32–34]. Dissatisfaction could be
one of the reasons for nonadherence and poor disease control.
The fact that the satisfaction profile of controlled patients is
different from that of noncontrolled patients raises an important
question: Is it lack of disease control that generates dissatisfac-
tion with treatment or does dissatisfaction with treatment,
through poor adherence, increase the probability of poor disease
control? The answer to this question will dictate whether the
clinician’s primary focus should be intensification of treatment to
achieve disease control or removing the causes of dissatisfaction
and thus improving medication adherence [35,36]. Whatever the
reasons, we need to develop accurate measures of treatment
satisfaction capable of distinguishing patients who benefit from
adequate treatment and sensitive to adjustments in patient
management.
Our study is not free of possible limitations. For instance, one
possible limitation involves the calculation of sample size, which
was determined by the original research, that is, testing variations in
pain intensity in subjects treated at pain clinics who change their
therapy. However, the final number of patients considered eligible for
analysis was large enough to conduct the statistical analysis
included in this research. It could also be argued that in this study,
only changes in pain therapy were explored. This is true, and
possibly the responsiveness of the SATMED-Q should be additionally
tested in other types of chronic health conditions. However, the
findings of this study are promising and sufficiently robust to support
the ability of the instrument to detect changes in patient satisfaction.
Table 6 – Known-group validity of the SATMED-Q by level of interference of pain with patient’s life at EOT visit as assessed by
the WHODAS II scale.
Domain Group by level of
interference at EOT visit
Mean 95% CI F (P value)
Treatment effectiveness None 86.1 80.1–92.1 33.2 (Po 0.001)
Mild 77.8 75.0–80.7
Moderate 61.8 58.6–65.0
Severe 50.3 45.1–55.5
Extreme 48.6 39.6–57.7
Convenience of use None 85.3 79.7–90.9 11.0 (Po 0.001)
Mild 75.4 72.8–78.1
Moderate 66.7 63.8–69.7
Severe 64.2 59.3–69.1
Extreme 69.5 61.1–77.9
Impact on activities of daily living None 84.1 78.4–89.9 49.7 (Po 0.001)
Mild 74.2 71.5–77.0
Moderate 57.6 54.5–60.6
Severe 42.9 37.8–48.0
Extreme 32.6 24.0–41.2
Medical care None 90.7 86.5–94.9 9.1 (Po 0.001)
Mild 87.0 84.9–89.0
Moderate 81.0 78.8–83.3
Severe 77.0 73.2–80.7
Extreme 76.8 70.5–83.2
Global satisfaction None 87.5 82.5–92.5 28.6 (Po 0.001)
Mild 84.9 82.5–87.3
Moderate 72.6 69.9–75.2
Severe 64.2 59.8–68.6
Extreme 55.7 48.2–63.1
Undesirable side effects None 96.9 90.5–103.3 19.3 (Po 0.001)
Mild 88.4 85.5–91.3
Moderate 78.4 75.3–81.6
Severe 67.5 62.3–72.6
Extreme 63.8 54.8–72.9
Total composite score None 87.8 83.7–92,0 44.2 (Po 0.001)
Mild 80.8 78.8–82.7
Moderate 69.0 66.9 –71.1
Severe 60.1 56.7–63.5
Extreme 57.2 51.3–63.1
Note. None (n ¼ 65; 9.8%), mild (n ¼ 267; 40%), moderate (n ¼ 217; 32.5%), severe (n ¼ 88; 13.2%), and extreme (n ¼ 30; 4.5%) groups of level of
interference of pain with patient’s life. Values are adjusted for baseline level of interference. Some patients did not complete the WHODAS
II scale.
CI, confidence interval; EOT, end of trial; SATMED-Q, Treatment Satisfaction with Medicines Questionnaire; WHODAS II, World Health
Organization Disability Assessment Schedule II.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 8 8 – 9 6 95However, drug interactions and comorbidities were not studied, and
the present design does not allow such inquiries. Whether patient
satisfaction with medicines may be affected because of these aspects
remains unknown at present. Also, the monitoring of side effects
was poor in this study because of its observational real-world design,
avoiding conducting a rigorous analysis of the impact of side effects
on patient satisfaction with therapy.Conclusion
In conclusion, and despite the above limitations, the SATMED-Q
has proven to be responsive to different levels of patient satisfac-
tion with therapy in chronically ill subjects and also sensitive to
changes in patient satisfaction with treatment in resistant
patients with pain of neuropathic origin. Taking into account
the salient aspect of the SATMED-Q, that it is generic in nature,
and the fact that few questionnaires currently offer this profile,the particular feature shown in this study makes the instrument
all the more useful.
Source of financial support: The work included in this article
did not receive any funding. The original data collection and
analysis carried out to develop the SATMED-Q received a grant
from Pfizer, S.L.U. Furthermore, the data used for this analysis
were extracted from a study that was funded by Pfizer, S.L.U.
Preliminary results of this study were presented at the 14th annual
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